Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.88) per share which met the analyst consensus estimate. This is a 83.33 percent decrease over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $3.03 million which missed the analyst consensus estimate of $8.59 million by 64.71 percent. This is a 94.62 percent decrease over sales of $56.38 million the same period last year.